<ARTICLE>             5

<LEGEND>

                             Financial Data Schedule
                     Mylan Laboratories Inc. and Subsidiaries
                           Article 5 of Regulation S-X


The schedule contains summary financial information extracted from
the Consolidated Balance Sheet at September 30, 1997 and the
Consolidated Statement of Earnings for the six months ended September
30, 1997 and is qualified in its entirety by reference to such
consolidated financial statements.


</LEGEND>
<CIK>                         0000069499  
<NAME>                        none
                                          
                                        
<PERIOD-TYPE>                          3-MOS            
<FISCAL-YEAR-END>                     MAR-31-1998             

<PERIOD-END>                          SEP-30-1997              
                                               
<CASH>                                 93,062,000              
<SECURITIES>                           18,774,000              
<RECEIVABLES>                         137,666,000              
<ALLOWANCES>                           20,131,000              
<INVENTORY>                           132,458,000              
<CURRENT-ASSETS>                      408,361,000              
<PP&E>                                208,662,000              
<DEPRECIATION>                         67,972,000              
<TOTAL-ASSETS>                        815,759,000              
<CURRENT-LIABILITIES>                  84,110,000              
<BONDS>                                38,929,000              
<PREFERRED-MANDATORY>                           0              
<PREFERRED>                                     0               
<COMMON>                               61,467,000              
<OTHER-SE>                            638,007,000              
<TOTAL-LIABILITY-AND-EQUITY>          815,759,000              
<SALES>                               236,321,000              
<TOTAL-REVENUES>                      263,143,000              
<CGS>                                 132,580,000              
<TOTAL-COSTS>                         132,580,000                     
<OTHER-EXPENSES>                       75,036,000          
<LOSS-PROVISION>                                0          
<INTEREST-EXPENSE>                      1,508,000          
<INCOME-PRETAX>                        68,382,000          
<INCOME-TAX>                           21,393,000          
<INCOME-CONTINUING>                    46,989,000          
<DISCONTINUED>                                  0          
<EXTRAORDINARY>                                 0          
<CHANGES>                                       0          
<NET-INCOME>                           46,989,000          
<EPS-PRIMARY>                                 .39          
<EPS-DILUTED>                                 .39